Fierce Biotech

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna Drops Vaccine for Birth Defects After Trial Failure

Moderna had hoped its shot would be at least 49% effective at preventing CMV infections, substantially reducing the risk of ...
pharmaphorum

Moderna drops mRNA jab for CMV after phase 3 fail

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

Moderna says key study of its CMV vaccine, expected to be its next big win, failed

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal ...
Healio

Ganciclovir prophylaxis shows no respiratory support-free day, mortality benefit in sepsis

Please provide your email address to receive an email when new articles are posted on . Studied adults had sepsis-associated respiratory failure and were cytomegalovirus seropositive. Those receiving ...
Seeking Alpha

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy ...

Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for ...